Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy

    October 2019 in “ JNCI Cancer Spectrum ”
    Hope S. Rugo, Johannes Ettl, Sara A. Hurvitz, Anthony Gonçalvès, Kyung-Hun Lee, Louis Fehrenbacher, Lida A. Mina, Sami Diab, Natasha Woodward, Rinat Yerushalmi, Annabel Goodwin, Joanne L. Blum, Miguel Martín, Ruben G.W. Quek, Iulia Cristina Tudor, Helen Bhattacharyya, Eric Gauthier, Jennifer K. Litton, W. Eiermann
    TLDR Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.
    The EMBRACA study was a phase III trial that compared talazoparib, a PARP inhibitor, with physician's choice chemotherapy (PCT) in 431 patients with advanced breast cancer and BRCA1/2 mutations. Talazoparib significantly improved progression-free survival and objective response rates across all patient subgroups compared to PCT, with hazard ratios of 0.47 for HR+/HER2− and 0.60 for TNBC subgroups. It also showed better patient-reported outcomes and delayed deterioration. Common adverse events included anemia and fatigue for talazoparib, and neutropenia and fatigue for PCT. Alopecia was observed in 2.4% of patients as grade II and 22.7% as grade I with talazoparib. Overall, talazoparib demonstrated clinically significant superiority in outcomes compared to PCT for patients with gBRCA-mutated advanced breast cancer.
    Discuss this study in the Community →